Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product?
The provision of concentrates of the deficient coagulation factors is an essential component of the provision of comprehensive haemophilia care. Their safety, quality and efficacy need to be assured independently of the measures dictated by the market and the individual manufacturers. Over the past 20 years, this assurance has become the role of regulatory authorities, which in the developed world have generated a framework that assesses haemophilia products as medicines in the highest category of risk relative to other therapeutic agents. Systems of official regulation mandating standards and other measures are now coupled with voluntary standards adopted by industry bodies as additional features of a comprehensive nexus of arrangements contributing to product quality and risk minimization. Currently, the regulation of products for haemophilia in less developed economies relies on reference to decisions in the first-world authorities. This may not always result in optimal outcomes as most of the haemophilia care in the developing world is through local plasma and cryoprecipitate, which are not subject to the oversight of mainstream regulators. Furthermore, the emergence of companies based outside the developed world and seeking to supply the emerging economies of the developing world with haemophilia concentrates has necessitated new strategies for regulation that are independent of the established frameworks. Overall, the principles used by mainstream agencies may be applied in all environments seeking to assure the quality of haemophilia care. Applied properly, they can contribute to maintaining the delivery of a form of therapy that is nowadays amongst the safest in therapeutic practice. A rigid interpretation can seriously impede access to treatment, and therefore the development of independent expertise and appropriate strategies in assuring product safety and quality in the developing world is essential if patient safety and access to products can be assured.
Farrugia
A
A
Blood and Tissues Unit, Office of Devices, Blood and Tissues, Australian Therapeutic Goods Administration, Woden ACT, Australia 2606. albert.farrugia@health.gov.au
D001779:Blood Coagulation Factors / Q000191:economics / Q000592:standards / Q000600:supply & distribution*; D003257:Consumer Product Safety; D003365:Costs and Cost Analysis; D003906:Developing Countries / Q000191:economics; D004335:Drug and Narcotic Control / Q000458:organization & administration / Q000639:trends*; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D007391:International Cooperation
D001779:Blood Coagulation Factors